{"id":23780,"date":"2011-12-29T12:51:17","date_gmt":"2011-12-29T18:51:17","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=23780"},"modified":"2018-04-14T02:07:50","modified_gmt":"2018-04-14T07:07:50","slug":"23780","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/23780\/","title":{"rendered":"Not\u00edcias e notas sobre sa\u00fade animal de 29 de dezembro de 2011"},"content":{"rendered":"

vers\u00e3o amig\u00e1vel para impressora<\/a><\/p>\n

************************************
\nBrakke Consulting's
\nNot\u00edcias e notas de sa\u00fade animal de 29 de dezembro de 2011
\n<\/strong>Copyright \u00a9 Brakke Consulting, Inc.
\n 
\nEditor: Lynn Fondon, DVM MBA
\n************************************
\nNAS NOTICIAS:
\n 
\nnot\u00edcias de Brakke<\/u> 
\nRegistro geral de 2012<\/p>\n

not\u00edcias de ganhos
\n<\/u>Neogen<\/p>\n

outras not\u00edcias
\n<\/u>Abaxis (dirofilariose felina)
\nAbaxis (doen\u00e7a de Lyme)
\nAvivagen
\nBiocora\u00e7\u00e3o
\nbioniche
\nMedTrade
\nCl\u00ednica Muller
\nNDI
\nStemlogix
\nVet-Stem
\nVirbac
\n 
\n***********************************
\nRELEASES DE RESULTADOS DA EMPRESA
\n 
\n> A Neogen Corporation anunciou os resultados do segundo trimestre do ano fiscal de 2012 encerrado em 30 de novembro. As receitas aumentaram 2% em rela\u00e7\u00e3o ao segundo trimestre do ano anterior para $45 milh\u00f5es. O lucro l\u00edquido do trimestre foi de $5,2 milh\u00f5es, um decl\u00ednio de 15% em compara\u00e7\u00e3o com o segundo trimestre do ano anterior. As receitas da Divis\u00e3o de Seguran\u00e7a Animal da Neogen aumentaram para $22,8 milh\u00f5es, de $22,6 milh\u00f5es no mesmo per\u00edodo do ano passado (comunicado \u00e0 imprensa da empresa)
\n 
\n************************************
\nCOMUNICADOS DE NOT\u00cdCIAS DA EMPRESA
\n 
\n> O FDA informou que aprovou o tratamento da Virbac para infec\u00e7\u00f5es de ouvido canino, Easotic. O produto sujeito a receita m\u00e9dica cont\u00e9m hidrocortisona, miconazol e gentamicina. (Farm\u00e1cia Animal)
\n 
\n> A Bioniche Animal Health anunciou que celebrou dois acordos de distribui\u00e7\u00e3o para expandir sua oferta de produtos na Am\u00e9rica do Norte. O primeiro acordo \u00e9 com a MedTrade Products, que fornecer\u00e1 uma s\u00e9rie de produtos para a sa\u00fade de equinos e animais de companhia baseados em sua tecnologia de tratamento de feridas Celox (quitosana) para distribui\u00e7\u00e3o exclusiva pela Bioniche no Canad\u00e1. O segundo acordo \u00e9 com a Mueller Medical International, dando \u00e0 Bioniche uma licen\u00e7a exclusiva para distribuir Equine Gastrafate no Canad\u00e1 e nos EUA. Equine Gastrafate \u00e9 uma composi\u00e7\u00e3o de sacar\u00eddeo patenteada usada por veterin\u00e1rios equinos que suspeitam de c\u00f3lica ulcerativa em cavalos. (Farm\u00e1cia Animal) 
\n 
\n> Abaxis, Inc. anunciou a adi\u00e7\u00e3o de um teste r\u00e1pido para dirofilariose felina \u00e0 sua crescente linha de produtos de diagn\u00f3stico r\u00e1pido. O USDA aprovou agora o uso do teste Abaxis VetScan Canine Heartworm Antigen para aplica\u00e7\u00f5es felinas. (PRNewswire)
\n 
\n> Abaxis Veterinary Reference Laboratories anunciou o desenvolvimento de um teste quantitativo de anticorpos para a doen\u00e7a de Lyme canina. O novo teste possui a capacidade de diferenciar uma infec\u00e7\u00e3o ativa de Lyme de uma imunidade baseada na vacina\u00e7\u00e3o e fornece o diagn\u00f3stico adequado necess\u00e1rio para um teste de confirma\u00e7\u00e3o realizado em laborat\u00f3rio de refer\u00eancia. (Zacks. com) 
\n 
\n> A NDI anunciou o lan\u00e7amento do GaitCheck, um dispositivo port\u00e1til sem fio que analisa a marcha de um cavalo trotando. O GaitCheck produz duas pontua\u00e7\u00f5es de marcha que s\u00e3o usadas para determinar se a marcha \u00e9 normal ou se h\u00e1 uma indica\u00e7\u00e3o de potencial claudica\u00e7\u00e3o nos membros anteriores ou posteriores. O GaitCheck foi testado de forma independente pelo McPhail Equine Performance Center da Michigan State University. (Transfer\u00eancia Comercial)
\n 
\n> A Bioheart, Inc. anunciou que celebrou um acordo com a Stemlogix, LLC para fornecer produtos e servi\u00e7os celulares adicionais ao mercado veterin\u00e1rio. Pelo acordo, as empresas oferecer\u00e3o cultura expandida de medula \u00f3ssea e c\u00e9lulas-tronco adiposas para uso em animais com doen\u00e7as degenerativas ou les\u00f5es agudas. Al\u00e9m disso, os pacientes veterin\u00e1rios ter\u00e3o a op\u00e7\u00e3o de armazenar suas c\u00e9lulas-tronco para uso futuro. (Globo Newswire)
\n 
\n> CANAD\u00c1 Chemaphor Inc. anunciou um acordo m\u00fatuo com a Vet-Stem Inc. para rescindir a licen\u00e7a emitida pela Vet-Stem \u00e0 subsidi\u00e1ria integral da Chemaphor, Avivagen Animal Health Inc., para a condu\u00e7\u00e3o da terapia celular regenerativa VetStem RC em animais de companhia no Canad\u00e1 , a fim de concentrar os recursos da empresa exclusivamente nas oportunidades de crescimento internacional apresentadas pela tecnologia OxC-beta da Chemaphor. (MercadoWire)
\n 
\n***********************************
\nNOT\u00cdCIAS DE SA\u00daDE ANIMAL
\n 
\n> HONG KONG \u2013 GRIPE AVI\u00c1RIA Hong Kong abateu 17.000 galinhas depois que foi confirmado que tr\u00eas aves morreram devido \u00e0 gripe avi\u00e1ria H5N1. O governo proibiu a importa\u00e7\u00e3o e a venda de frangos vivos durante tr\u00eas semanas. Duas aves selvagens tamb\u00e9m morreram do v\u00edrus. O governo disse que estava rastreando a origem da carca\u00e7a do frango, mas n\u00e3o estava claro se o frango vinha de uma fazenda local ou era importado. (BBC Not\u00edcias)
\n 
\n> EUA \u2013 LEGISLA\u00c7\u00c3O DE ABATE DE SU\u00cdNOS Os ju\u00edzes da Suprema Corte dos EUA decidir\u00e3o se a lei da Calif\u00f3rnia pode impedir o abate de su\u00ednos incapazes de andar no estado. No caso National Meat Association v. Harris, a organiza\u00e7\u00e3o da ind\u00fastria da carne est\u00e1 lutando contra a legisla\u00e7\u00e3o aprovada em janeiro de 2008 que exige a eutan\u00e1sia imediata de qualquer animal que n\u00e3o consiga andar em um matadouro inspecionado pelo governo federal. O governo federal est\u00e1 apoiando o apelo da ind\u00fastria. A associa\u00e7\u00e3o argumentou que as regulamenta\u00e7\u00f5es federais regem o manejo de su\u00ednos cansados e estressados, que geralmente conseguem ficar de p\u00e9 e andar ap\u00f3s descanso e supervis\u00e3o e n\u00e3o ficam incapacitados por causa de doen\u00e7as. Enquanto o juiz do Tribunal Distrital dos EUA emitiu em Fevereiro de 2009 uma liminar contra a aplica\u00e7\u00e3o da lei nos matadouros de su\u00ednos, o 9\u00ba Tribunal de Apela\u00e7\u00f5es do Circuito dos EUA anulou a decis\u00e3o em Mar\u00e7o de 2010. (Vet Advantage, JAVMA)
\n 
\n***********************************
\nBRAKKE CONSULTING, INC.
\nREGISTRE-SE AGORA PARA VISUALIZA\u00c7\u00c3O DA IND\u00daSTRIA
\n<\/strong> 
\nA Brakke Consulting apresentar\u00e1 a Vis\u00e3o Geral da Ind\u00fastria de Sa\u00fade Animal dos EUA de 2012 duas vezes neste inverno \u2013 uma vez na Confer\u00eancia Veterin\u00e1ria Norte-Americana em Orlando, Fl\u00f3rida, e outra vez na Confer\u00eancia Veterin\u00e1ria Ocidental em Las Vegas, Nevada. Essas datas s\u00e3o:
\n\u2022 NAVC: segunda-feira, 16 de janeiro, das 14h \u00e0s 16h, no Gaylord Palms.
\n\u2022 WVC: ter\u00e7a-feira, 21 de fevereiro, das 14h \u00e0s 16h no Four Seasons.
\nAs inscri\u00e7\u00f5es para o Industry Overview no NAVC e WVC j\u00e1 est\u00e3o abertas. Para se inscrever acesse www.brakkeconsulting.com<\/a> e role para baixo at\u00e9 a caixa "O que h\u00e1 de novo". O pre\u00e7o \u00e9 $375 por pessoa para inscri\u00e7\u00e3o online; registro tardio \u00e9 $425.
\n 
\nwww.BrakkeConsulting.com<\/a>
\n <\/p>\n

************************************
\nPONTO DE VISTA DA BRAKKE CONSULTORIA
\n 
\nN\u00f3s da Brakke Consulting desejamos a todos voc\u00eas um feliz e pr\u00f3spero ano novo.
\n 
\nRon Brakke
\nJoel Adamson
\nKen Berkholtz
\nRay Collier
\nLynn Fondon
\nAtsuo Hata
\nJ\u00e9ssica Lee
\nJay Lockhart
\nJohn Mannhaupt
\nSusan Mannhaupt
\nRichard Miles
\nJane Morgan
\nKevin Scott
\nJohn Volk
\nSusan Warren
\n 
\n************************************
\nProblemas para visualizar esta newsletter? Voc\u00ea pode visualiz\u00e1-lo online em www.BrakkeConsulting.com<\/a>
\nEste boletim eletr\u00f4nico \u00e9 propriedade exclusiva da Brakke Consulting, Inc.
\nQualquer uso do conte\u00fado deste documento deve ser aprovado e devidamente atribu\u00eddo \u00e0 Brakke Consulting, Inc.
\nPara obter mais informa\u00e7\u00f5es sobre os servi\u00e7os e estudos sindicados da Brakke Consulting, visite nosso website em www.brakkeconsulting.com<\/a>.
\n 
\nBrakke Consulting, Inc.
\n12005 Ford Rd., Suite 530
\nDallas, TX 75234 EUA<\/p>","protected":false},"excerpt":{"rendered":"

vers\u00e3o para impress\u00e3o ************************************ Not\u00edcias e notas sobre sa\u00fade animal da Brakke Consulting para 29 de dezembro de 2011 Copyright \u00a9 Brakke Consulting, Inc. Editor: Lynn Fondon, DVM MBA ************************************ NAS NOT\u00cdCIAS: Vis\u00e3o geral das not\u00edcias da Brakke de 2012 registro ganhos not\u00edcias Neogen outras not\u00edcias Abaxis (verme do cora\u00e7\u00e3o felino) Abaxis (doen\u00e7a de Lyme) Avivagen Bioheart Bioniche MedTrade Mueller Medical NDI Stemlogix Vet-Stem Virbac *********************************** DIVULGA\u00c7\u00d5ES DE RESULTADOS DA EMPRESA > A Neogen Corporation anunciou os resultados do segundo trimestre do ano fiscal de 2012 encerrado em 30 de novembro. As receitas aumentaram 2% em rela\u00e7\u00e3o ao segundo trimestre do ano fiscal de 2012, para $45 milh\u00f5es. O lucro l\u00edquido do trimestre foi de $5,2 milh\u00f5es, um decl\u00ednio de 15% em compara\u00e7\u00e3o ao segundo trimestre do ano anterior. As receitas da Divis\u00e3o de Seguran\u00e7a Animal da Neogen aumentaram para $22,8 milh\u00f5es de $22,6 milh\u00f5es no mesmo per\u00edodo do ano passado (comunicado \u00e0 imprensa da empresa) ************************************ COMUNICADOS \u00c0 IMPRENSA DA EMPRESA > O FDA informou que aprovou o tratamento da Virbac para infec\u00e7\u00f5es de ouvido caninas, Easotic. O produto de prescri\u00e7\u00e3o cont\u00e9m hidrocortisona, miconazol e gentamicina. (Animal Pharm) > A Bioniche Animal Health anunciou que firmou dois acordos de distribui\u00e7\u00e3o para expandir suas ofertas de produtos na Am\u00e9rica do Norte. O primeiro acordo \u00e9 com a MedTrade Products, que fornecer\u00e1 uma s\u00e9rie de produtos de sa\u00fade para equinos e animais de companhia com base em sua tecnologia de tratamento de feridas Celox (quitosana) para distribui\u00e7\u00e3o exclusiva pela Bioniche no Canad\u00e1. O segundo acordo \u00e9 com<\/p>\n

Ver postagem completa<\/a><\/div>\n

;<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-23780","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"\nNews from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/23780\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"printer freindly version ************************************ Brakke Consulting’s Animal Health News & Notes for December 29, 2011 Copyright © Brakke Consulting, Inc.   Editor: Lynn Fondon, DVM MBA ************************************ IN THE NEWS:   Brakke news  2012 Overview registration earnings news Neogen other news Abaxis (feline heartworm) Abaxis (Lyme disease) Avivagen Bioheart Bioniche MedTrade Mueller Medical NDI Stemlogix Vet-Stem Virbac   *********************************** COMPANY EARNINGS RELEASES   > Neogen Corporation announced results for the second quarter of FY 2012 ended Nov. 30. Revenues increased 2% from the previous year’s second quarter to $45 million. Net income for the quarter was $5.2 million, a decline of 15% compared to the prior year’s second quarter. Neogen’s Animal Safety Division revenues increased to $22.8 million from $22.6 million in the same period last year (company press release)   ************************************ COMPANY NEWS RELEASES   > The FDA reported it has approved Virbac’s treatment for canine ear infections, Easotic. The prescription-only product contains hydrocortisone, miconazole and gentamycin. (Animal Pharm)   > Bioniche Animal Health announced that it has entered into two distribution agreements to expand its product offerings in North America.  The first agreement is with MedTrade Products, which will provide a number of equine and companion animal health products based on its Celox (chitosan) woundcare technology for exclusive distribution by Bioniche in Canada. The second agreement is withView Full Post;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/23780\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2011-12-29T18:51:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-04-14T07:07:50+00:00\" \/>\n<meta name=\"author\" content=\"Brakke Consulting\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brakke Consulting\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/23780\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/23780\/\"},\"author\":{\"name\":\"Brakke Consulting\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6\"},\"headline\":\"Animal Health News & Notes for December 29, 2011\",\"datePublished\":\"2011-12-29T18:51:17+00:00\",\"dateModified\":\"2018-04-14T07:07:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/23780\/\"},\"wordCount\":1023,\"articleSection\":[\"Newsletter\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/23780\/\",\"url\":\"https:\/\/brakkeconsulting.com\/23780\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2011-12-29T18:51:17+00:00\",\"dateModified\":\"2018-04-14T07:07:50+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/23780\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/23780\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/23780\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Animal Health News & Notes for December 29, 2011\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6\",\"name\":\"Brakke Consulting\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/author\/i5ww2018\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/23780\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"printer freindly version ************************************ Brakke Consulting’s Animal Health News & Notes for December 29, 2011 Copyright © Brakke Consulting, Inc.   Editor: Lynn Fondon, DVM MBA ************************************ IN THE NEWS:   Brakke news  2012 Overview registration earnings news Neogen other news Abaxis (feline heartworm) Abaxis (Lyme disease) Avivagen Bioheart Bioniche MedTrade Mueller Medical NDI Stemlogix Vet-Stem Virbac   *********************************** COMPANY EARNINGS RELEASES   > Neogen Corporation announced results for the second quarter of FY 2012 ended Nov. 30. Revenues increased 2% from the previous year’s second quarter to $45 million. Net income for the quarter was $5.2 million, a decline of 15% compared to the prior year’s second quarter. Neogen’s Animal Safety Division revenues increased to $22.8 million from $22.6 million in the same period last year (company press release)   ************************************ COMPANY NEWS RELEASES   > The FDA reported it has approved Virbac’s treatment for canine ear infections, Easotic. The prescription-only product contains hydrocortisone, miconazole and gentamycin. (Animal Pharm)   > Bioniche Animal Health announced that it has entered into two distribution agreements to expand its product offerings in North America.  The first agreement is with MedTrade Products, which will provide a number of equine and companion animal health products based on its Celox (chitosan) woundcare technology for exclusive distribution by Bioniche in Canada. The second agreement is withView Full Post;","og_url":"https:\/\/brakkeconsulting.com\/pt\/23780\/","og_site_name":"Brakke Consulting Website","article_published_time":"2011-12-29T18:51:17+00:00","article_modified_time":"2018-04-14T07:07:50+00:00","author":"Brakke Consulting","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Brakke Consulting","Tempo estimado de leitura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/23780\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/23780\/"},"author":{"name":"Brakke Consulting","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6"},"headline":"Animal Health News & Notes for December 29, 2011","datePublished":"2011-12-29T18:51:17+00:00","dateModified":"2018-04-14T07:07:50+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/23780\/"},"wordCount":1023,"articleSection":["Newsletter"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/23780\/","url":"https:\/\/brakkeconsulting.com\/23780\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2011-12-29T18:51:17+00:00","dateModified":"2018-04-14T07:07:50+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/23780\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/23780\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/23780\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Animal Health News & Notes for December 29, 2011"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6","name":"Brakke Consultoria","url":"https:\/\/brakkeconsulting.com\/pt\/author\/i5ww2018\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=23780"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23780\/revisions"}],"predecessor-version":[{"id":25328,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23780\/revisions\/25328"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=23780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=23780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=23780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}